Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

BACKGROUND: Though the precise cause(s) of Alzheimer’s disease (AD) remain unknown, there is strong evidence that decreased clearance of β-amyloid (Aβ) from the brain can contribute to the disease. Therapeutic strategies to promote natural Aβ clearance mechanisms, such as the protein apolipoprotein-...

Descripción completa

Detalles Bibliográficos
Autores principales: LaClair, Katherine D, Manaye, Kebreten F, Lee, Dexter L, Allard, Joanne S, Savonenko, Alena V, Troncoso, Juan C, Wong, Philip C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693923/
https://www.ncbi.nlm.nih.gov/pubmed/23764200
http://dx.doi.org/10.1186/1750-1326-8-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693923/
https://www.ncbi.nlm.nih.gov/pubmed/23764200
http://dx.doi.org/10.1186/1750-1326-8-18

Ejemplares similares